Publications by authors named "Jay Backstrom"

Claim this Profile
H
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Maria Domenica Cappellini, Ali T Taher, Antonio Piga, Farrukh Shah, Ersi Voskaridou, Jay T Backstrom

Eur J Haematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Amer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, Mikkael A Sekeres, Pierre Fenaux, Jay T Backstrom

Blood· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Ali T Taher, Maria Domenica Cappellini, Antonis Kattamis, Ersi Voskaridou, Silverio Perrotta, Jay T Backstrom

Lancet Haematol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Rami S Komrokji, Uwe Platzbecker, Pierre Fenaux, Amer M Zeidan, Guillermo Garcia-Manero, Jay T Backstrom

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Guillermo Garcia-Manero, Ghulam J Mufti, Pierre Fenaux, Rena Buckstein, Valeria Santini, Jay T Backstrom

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Esther Natalie Oliva, Uwe Platzbecker, Guillermo Garcia-Manero, Ghulam J Mufti, Valeria Santini, Jay T Backstrom

J Clin Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
REMS pharmacy tasks: The adoption of an innovative electronic support system.
May L Chan-Liston, Jennifer L Bourke, Robin McWilliams, Paul Sheehan, Jennifer Chapman, Jay T Backstrom

J Am Pharm Assoc (2003)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teratogenic Drugs and Risk Management: An Implementation Assessment.
John Freeman, Robert Bwire, Florence Houn, Paul Sheehan, Jay Backstrom

Ther Innov Regul Sci· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
Leonie Saft, Mohsen Karimi, Mehran Ghaderi, András Matolcsy, Ghulam J Mufti, Jay Backstrom

Haematologica· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.
John F Seymour, Pierre Fenaux, Lewis R Silverman, Ghulam J Mufti, Eva Hellström-Lindberg, Jay Backstrom

Crit Rev Oncol Hematol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
Valeria Santini, Pierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, Lewis R Silverman, Jay Backstrom

Eur J Haematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Pierre Fenaux, Norbert Gattermann, John F Seymour, Eva Hellström-Lindberg, Ghulam J Mufti, Jay Backstrom

Br J Haematol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
Pierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, Valeria Santini, Norbert Gattermann, Jay Backstrom

J Clin Oncol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Roger M Lyons, Thomas M Cosgriff, Sanjiv S Modi, Robert H Gersh, John D Hainsworth, Jay T Backstrom

J Clin Oncol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Jay Backstrom

Lancet Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Lewis R Silverman, David R McKenzie, Bercedis L Peterson, James F Holland, Jay T Backstrom

J Clin Oncol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis